Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
CERE was delisted on the 31st of July, 2024.
107 hedge funds and large institutions have $3.82B invested in Cerevel Therapeutics Holdings, Inc. Common Stock in 2021 Q4 according to their latest regulatory filings, with 27 funds opening new positions, 43 increasing their positions, 27 reducing their positions, and 13 closing their positions.
294% more call options, than puts
Call options by funds: $17M | Put options by funds: $4.33M
108% more first-time investments, than exits
New positions opened: 27 | Existing positions closed: 13
59% more repeat investments, than reductions
Existing positions increased: 43 | Existing positions reduced: 27
14% more funds holding
Funds holding: 94 → 107 (+13)
9% more capital invested
Capital invested by funds: $3.49B → $3.82B (+$328M)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
+$25.7M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$24.8M |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$7.17M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$5.65M |
| 5 |
BlackRock
New York
|
+$4.28M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Alkeon Capital Management
New York
|
-$43M |
| 2 |
Alyeska Investment Group
Chicago,
Illinois
|
-$12.5M |
| 3 |
Invesco
Atlanta,
Georgia
|
-$11.9M |
| 4 |
AG
Artal Group
Luxembourg
|
-$10.6M |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$8.43M |
CERE Hedge Fund Activity: Q4 2021 in Review
107 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Cerevel Therapeutics Holdings, Inc. Common Stock (CERE) for Q4 2021, worth a combined $3.82B — up 9.4% from $3.49B a quarter earlier.
Buyers outnumbered sellers: 27 funds opened new CERE positions and 13 closed out — a net gain of 14 holders — while 43 added to existing stakes and 27 trimmed.
The largest buyer was Lord, Abbett & Co, opening a new position worth an estimated $25.7M. The largest seller was Alkeon Capital Management, cutting an estimated $43M.
- 107 institutional investors held Cerevel Therapeutics Holdings, Inc. Common Stock (CERE) as of Q4 2021, up from 94 in Q3 2021.
- Funds reported $3.82B of Cerevel Therapeutics Holdings, Inc. Common Stock stock for Q4 2021, up 9.4% quarter-over-quarter.
- 27 funds opened new Cerevel Therapeutics Holdings, Inc. Common Stock positions in Q4 2021 and 13 closed out, a net change of +14 holders.
- The largest Cerevel Therapeutics Holdings, Inc. Common Stock buyer in Q4 2021 was Lord, Abbett & Co, an estimated $25.7M added.
- The largest Cerevel Therapeutics Holdings, Inc. Common Stock seller in Q4 2021 was Alkeon Capital Management, an estimated $43M sold.
Based on aggregated 13F filings for Q4 2021.